Rodman & Renshaw Reiterates Agenus Market Perform, $2 PT

Rodman & Renshaw reiterated its Agenus AGEN Market Perform rating and $2 price target in a research report published today. In the report, Rodman & Renshaw states, " We are reiterating our Market Outperform / Speculative Risk rating on Agenus with a 12-month target price of $2, based on a comparable company analysis to value the oncology programs in combination with a net present value analysis for the potential contribution of future QS-21 royalty revenue to the company's valuation." Shares of Agenus were trading at $0.81 at the time of posting, down 0.61% from Thursday's market close.